

New monolithic chiral stationary phases for the enantioselective nano-liquid chromatographic separation of racemic pharmaceuticals

by

Marwa Ahmed

A Thesis submitted in fulfilment of the requirements for the degree

of

Doctor of Philosophy



**UNIVERSITY OF
CANBERRA**

AUSTRALIA'S CAPITAL UNIVERSITY

Australian Capital Territory, Australia

March 2015

Acknowledgments

Sincerest gratitude is expressed toward my primary supervisor, A/Prof. Dr. Ashraf Ghanem for firstly accepting me to join his project at the University of Canberra. Thanks are due for his continuous support and supervision throughout this research. It would have never been possible for this thesis to appear without his enormous support. Dr. Ghanem has also generously offered me extracurricular opportunities such as student secretary of the Royal Australian Chemical Institute (RACI), promotion of science events and teaching Chemistry courses for undergrads. These activities have significantly enriched my communication as well as academic skills.

My deepest gratitude is also expressed to the University of Canberra for offering me W J Weeden postgraduate research scholarship to pursue my PhD. Thanks are also due to the Schlumberger Foundation Faculty for the Future award.

Thanks are due to my co-supervisor Prof. Bill Maher for the wonderful support during the writing stage.

I am so grateful to the academic skills centre at the University of Canberra, Dr. Joelle Vandermensbrughe and Dr. Linda Li for the wonderful workshops which assisted me in improving my writing from the early beginning.

I would like to thank CSIRO Materials Science and Engineering, NSW for the fruitful collaboration. Thanks are due to Dr. Khaled Mriziq, Eksigent (California, USA) for the gifted capillary columns used in Chapter 6.

My sincere appreciation is for Dr. Karsten Gömann, Central Science Laboratory, University of Tasmania for the SEM imaging.

My sincerest gratitude goes to my former and current lab colleagues, including Dr. Ahmed Abdellah, Rob, Frady, Viji, Haysam, Marina, Nana and Vijay who have been such a wonderful and a fully supportive team. I would like to thank Tomoyuki Okada, Kyoto Institute of Technology, for visiting the Chirality group and sharing his experience in preparing silica monoliths in Canberra.

No words can express my gratitude for my family overseas; my parents, my sisters and my brother and my great friends here in Australia and overseas. I would also like to thank Dr. Rosemary Purdie for the helpful comments on my writing. It has been one of the toughest challenges of my life and I am quite sure I would have never been able to pass through without your support and encouragement. Nonetheless, the knowledge and wisdom I have gained through these years are indefinitely precious and rewarding and had made me the person I hope you would be proud of.

List of publications

Papers in refereed journals and in preparation

1. **Marwa Ahmed**, Tamsin Kelly and Ashraf Ghanem, “Applications of enzymes to access enantiomerically pure compounds; using kinetic resolution and racemisation” *Tetrahedron*, 68, 6781-6802, 2012.
2. Cara E. Humphrey, **Marwa Ahmed**, Ashraf Ghanem and Nicolas J. Turner, “Applications of enzymes in kinetic resolutions, dynamic kinetic resolutions and deracemization reactions” *Separation of Enantiomers: Synthetic Methods, First Edition*. Edited by Matthew Todd, Wiley-VCH Verlag GmbH & Co, ISBN: 978-3-527-33045-4,123-160, 2014.
3. **Marwa Ahmed** and Ashraf Ghanem, “Enantioselective nano liquid chromatographic separation of racemic pharmaceuticals: a facile one-pot *in situ* preparation of lipase-based polymer monoliths in capillary format” *Chirality*, 26, 754-763, 2014.
4. **Marwa Ahmed** and Ashraf Ghanem, “Chiral β -cyclodextrin functionalized polymer monolith for the direct enantioselective reversed phase nano liquid chromatographic separation of racemic pharmaceuticals” *Journal of Chromatography A*, 1345, 115-127, 2014.
5. **Marwa Ahmed**, Mir Massoud Aghili Yajadda, Zhao Jun Han, Dawei Su, Guoxiu Wang, Kostya (Ken) Ostrikov and Ashraf Ghanem, “Single-walled carbon nanotube-based polymer monoliths for the enantioselective nano-liquid chromatographic separation of racemic pharmaceuticals” *Journal of Chromatography A*, 1360, 100-109, 2014.

6. Ashraf Ghanem, **Marwa Ahmed**, Hideaki Ishii and Tohru Ikegami, “Immobilized β -cyclodextrin-based silica vs. polymer monoliths for chiral nano-liquid chromatographic separation of racemates” *Talanta*, 132, 301-314, 2015.
7. **Marwa Ahmed**, Marina Gwairgi and Ashraf Ghanem, “Conventional chiralpak ID vs. capillary chiralpak ID-3 amylose tris-(3-chlorophenylcarbamate)-based chiral stationary phase columns for the enantioselective HPLC separation of pharmaceutical racemates” *Chirality*, 26, 677-682, 2014.

Conference presentations

1. **Marwa Ahmed** and Ashraf Ghanem, “New silica bonded chiral β -cyclodextrin based capillary column for enantioselective separation of different classes of pharmaceuticals”, *Chirality* 2012, Fort Worth, Texas, USA.
2. **Marwa Ahmed** and Ashraf Ghanem, “Chiral and achiral polymer monolithic columns for separation of a mixture of different classes of pharmaceuticals using nano-HPLC”, *HPLC* 2012, Anaheim, USA.
3. **Marwa Ahmed** and Ashraf Ghanem, “New silica bonded β -cyclodextrin-based capillary column for enantioselective nano liquid chromatographic separation of different classes of pharmaceuticals”, *HPLC* 2013, Hobart, Australia.
4. **Marwa Ahmed** and Ashraf Ghanem, “Enantioselective nano liquid chromatographic separation of racemic pharmaceuticals: a facile one-pot *in situ* preparation of lipase-based polymer monoliths in capillary format”, *HPLC* 2013, Hobart, Australia.

5. **Marwa Ahmed** and Ashraf Ghanem, “Chiral β -cyclodextrin functionalized polymer monolith for the direct enantioselective reversed phase nano liquid chromatographic separation of racemic pharmaceuticals”, RACI R&D Topics 2013, Canberra, Australia.
6. Ashraf Ghanem, **Marwa Ahmed**, Mir Massoud Aghili Yajadda, Zhao Jun Han, Kostya (Ken) Ostrikov, “Single-walled carbon nanotube-based polymer monoliths for the enantioselective nano-liquid chromatographic separation of racemic pharmaceuticals”, Chirality 2014, Prague, Czech Republic.
7. Ashraf Ghanem and **Marwa Ahmed**, “New Lipase-based polymer monoliths for the enantioselective nano-liquid chromatographic separation of racemic pharmaceuticals”, Chirality 2014, Prague, Czech Republic.
8. Ashraf Ghanem and **Marwa Ahmed**, “Preparation of a novel β -cyclodextrin functionalized polymer monolith for the enantioselective nano-liquid chromatographic separation of racemic pharmaceuticals, Chirality 2014, Prague, Czech Republic.

Abstract

Pharmaceutical enantiomers have distinctive stereoselective binding interactions with the biological receptors and consequently enantiomers of a single drug may be considerably different in their pharmacokinetic and pharmacodynamic properties. As chiral drugs constitute approximately one-third of all drug sales worldwide, regulatory authorities such as the US Food and Drug Administration (FDA) have strict requirements to approve new chiral entities. Commercialization of enantiomerically pure drugs was previously considered a desirable challenge with many practical limitations. Nowadays, the technical advances of chiral separation and asymmetric synthesis allowed the availability of many single enantiomers on a commercial scale. Compared to the various available techniques to access enantiomerically pure drugs, separation of racemic mixtures has been demonstrated to be economically more feasible than diastereomeric crystallization or asymmetric synthesis to produce single enantiomers on a commercial scale.

Different separation techniques are available for the separation of racemic mixtures, such as Gas Chromatography (GC), High Performance Liquid Chromatography (HPLC), Supercritical Fluid Chromatography (SFC), Capillary Electrophoresis (CE) and Capillary Electrochromatography (CEC). Among them, HPLC is the workhorse of chiral separations for industrial applications. Miniaturization of conventional HPLC to nano-HPLC enables high throughput, reduced sample size and small consumption of hazardous solvents and consequently the chiral separation can be achieved under environmentally friendly conditions.

Monolithic stationary phases have been known for the past three decades. They are composed of a single piece of porous material through which the mobile phase percolates leading to the

chromatographic separation. Monoliths enable high mobile phase flow rate and hence faster separation compared to the particle-packed columns.

This thesis is concerned with the development of new monolithic chiral stationary phases in hair-thin columns called capillary columns for the chiral separation of thirteen classes of racemic pharmaceuticals using nano-HPLC. In this research, three chiral selectors namely lipase, β -cyclodextrin and single-walled carbon nanotubes were used for the preparation of polymer- or silica-based monolithic chiral stationary phases in capillary format. Different approaches were adopted for the preparation of the capillary columns; columns' reproducibility was also investigated to ensure their efficiency for industrial applications.

Table of contents

Acknowledgments.....	iii
List of publications.....	v
Abstract	ix
List of Figures	xvii
List of Tables.....	xxix
Abbreviations.....	xxxii
Form B	
Certificate of Authorship of Thesis.....	
Chapter 1	1
Monolithic capillary chiral stationary phases for the enantioselective separation of pharmaceuticals.....	1
1.1. The mystery of chirality.....	1
1.2. Chirality in drug design and development.....	2
1.2.1. Implications of drug chirality.....	3
1.2.2. Economic consequences for bioactive drug development.....	8
1.3. Different tools to access enantiomerically pure compounds	9
1.4. Chiral recognition principles.....	12
1.5. Enantioselective separation by means of nano-liquid chromatography (nano-LC)	17
1.6. Monolithic stationary phases	20
1.6.1. Organic polymer-based monolithic columns.....	21
1.6.2. Silica-based monolithic columns.....	30
1.6.3. Organic polymer versus silica monoliths.....	32

1.7. Monolithic capillary chiral stationary phases	35
1.7.1. Organic polymer-based monolithic CSPs	35
1.7.2. Silica-based monolithic CSPs	42
1.8. Objectives and aims of the study	50
1.9. References	51
Chapter 2	65
Experimental	65
2.1. Instrumentation	65
2.2. Reagents	66
2.2.1. Chemicals used for polymer monoliths preparations	66
2.2.2. Chemicals used for silica monoliths preparations	68
2.2.3. HPLC solvents	68
2.2.4. Chemicals used as analytes	69
2.2.5. Other chemicals	74
2.2.6. Investigated chiral selectors	75
2.3. Procedures	76
2.3.1. Sample preparations	76
2.3.2. Surface modification in fused silica capillaries for polymer monolith	76
2.3.3. Synthesis of polymer monoliths in surface modified capillaries	77
2.3.4. Surface modification in fused silica capillaries for silica monolith	79
2.3.5. Preparation of silica monolith	79
2.3.6. Scanning electron microscopy (SEM)	83
2.4. Calculations	83
2.4.1. Retention factors	83
2.4.2. Columns permeability based on Darcy's law	84
2.4.3. Column efficiency	84
2.4.4. Efficiency of the enantioselective separation	85
2.5. References	86

Chapter 3	87
Preparation of lipase-based new chiral stationary phases for enantioselective separation of pharmaceuticals using nano-LC.....	87
Part A: Establishing polymer monolith backbone	87
3A.1. Introduction	87
3A.2. Experimental	91
3A.2.1. Preparation of porous polymer monoliths in fused silica capillaries.....	91
3A.2.2. Sample preparations.....	92
3A.2.3. HPLC conditions	93
3A.3. Results and discussion	93
3A.3.1. Polymer monoliths preparation and characterization	93
3A.3.2. Chromatographic characterization of the prepared monoliths.....	99
3A.3.3. Columns repeatability	103
Part B: Induction of chirality, preparation of lipase-based CSPs	105
3B.1. Introduction	105
3B.2. Experimental	109
3B.2.1. Preparation of immobilized lipase-based monolith	109
3B.2.2. Preparation of encapsulated lipase-based monolith.....	112
3B.2.3. Combined immobilized and encapsulated lipase-based polymer monolith.....	113
3B.2.4. Sample preparations.....	114
3B.2.5. Preparation of ibuprofen butanoate.....	114
3B.2.6. Continuous flow Kinetic resolution of ibuprofen butanoate using the microreactor	114
3B.2.7. HPLC conditions.....	115
3B.3. Results and discussion.....	115
3B.3.1. Induction of chirality via lipase immobilization/encapsulation.....	115
3B.3.2. Chromatographic Characterization: Enantioselective nano-LC separation	122
3B.3.3. Insights into the chiral recognition mechanism	134

3B.3.4. Enantioselective hydrolysis of ibuprofen butanoate	137
3.4. Conclusions	139
3.5. References	140
Chapter 4	147
Preparation of new β -cyclodextrin-based monolithic chiral stationary phases for the enantioselective separation of pharmaceuticals using nano-LC	147
4.1. Introduction	147
4.2. Experimental	152
4.2.1. Preparation of the monolithic columns	153
4.2.2. Standard solutions and sample preparation	158
4.2.3. HPLC conditions	158
4.3. Results and discussion	158
4.3.1. Polymer monoliths: preparation and characterization	158
4.3.2. Silica monoliths: preparation and characterization	165
4.3.3. Enantioselective separation of different classes of pharmaceutical racemates using polymer- and silica-based monoliths	170
4.3.4. Insights into the chiral recognition mechanism	184
4.4. Conclusions	186
4.5. References	187
Chapter 5	191
Preparation of single-walled carbon nanotubes-based new chiral stationary phases for the enantioselective separation of pharmaceuticals using nano-LC	191
5.1. Introduction	191
5.2. Experimental	195
5.2.1. Preparation of porous polymer monoliths in fused silica capillaries	195
5.2.2. Sample preparations	196
5.2.3. HPLC conditions	196

5.3. Results and discussion	197
5.3.1. Characterizations of SWCNTs.....	197
5.3.2. Polymer monoliths: preparation and characterization	199
5.3.3. Enantioseparation of different classes of pharmaceutical racemates under multimodal elution.....	206
5.3.4. Insights into the chiral recognition mechanism	215
5.4. Conclusions.....	217
5.5. References.....	218
Chapter 6.....	221
Amylose tris-(3-chlorophenylcarbamate) for the enantioselective separation of pharmaceutical racemates using conventional HPLC and capillary-LC	221
6.1. Introduction.....	221
6.2. Experimental.....	223
6.2.1. Instrumentation.....	223
6.2.2. Sample preparations	223
6.2.3. HPLC conditions	223
6.3. Results and discussion	224
6.3.1. Enantioselective separation of the pharmaceutical racemates.....	225
6.3.2. Miniaturization of chiral separations, a future perspective.....	233
6.4. Conclusions.....	234
6.5. References.....	235
Chapter 7.....	237
Conclusions and future directions.....	237

List of Figures

Figure 1.1: Schematic diagram showing the three-point receptor theory. Only an enantiomer with the correct spatial arrangements of groups will provide effective complimentary interactions with the receptor ⁶	3
Figure 1.2: Chemical structures of thalidomide enantiomers	3
Figure 1.3: Worldwide revenue of chiral technology market 2009-2016, reproduced from reference ¹²	5
Figure 1.4: Chemical structures of propranolol enantiomers.....	6
Figure 1.5: Chemical structures of quinine and quinidine	6
Figure 1.6: Chemical structures of dobutamine enantiomers	7
Figure 1.7: General chemical structures for profens enantiomers	7
Figure 1.8: Schematic diagram showing different methods to access enantiomerically pure compounds ¹⁸	9
Figure 1.9: Schematic diagram showing the 1933 Easson–Stedman model, reproduced with permission from references ^{52,53} . Priority sequence for groups around the tetrahedron carbon is $a>b>c>d$. The binding sites for a, b, and c are represented as A, B, and C. In the Easson–Stedman model (A), the <i>R</i> -enantiomer can bind at all three sites (perfect fit) and hence is capable of eliciting biological response. However in (B) the <i>S</i> -enantiomer binding is limited to a single contact point. The alternative possibility for <i>S</i> enantiomers is shown in (C), where steric hindrance of d blocks the binding due to the large distance (double arrow) between a-A, b-B and c-C. From the interior, the approach of the <i>S</i> enantiomers is also not allowed (D).....	13
Figure 1.10: The “three-point interaction model” adapted to be relevant to the interactions occurring in a theoretical liquid chromatographic system. Included are thermodynamic contributions to Gibbs free energy of the CS-SA complexation according to the equation: $\Delta G(\text{CS-SA}/\text{binding}) = \Delta G_{\text{solv}} + \Delta G_{\text{int}} + \Delta G_{\text{conf}} + \Delta G_{\text{motion}}$. Proposed by and reproduced with	

permission from reference ⁵² . Shown is the interaction of ideal fit between S-SA and the non-interaction of the R-SA	15
Figure 1.11: Conventional HPLC a) with columns of 4.6 mm ID d) vs nano-LC b) with capillary columns of 10-300 μm ID d). The droplet waste coming off the nano-LC system is also shown in c)	18
Figure 1.12: Photograph of the porous monolith erected at the entrance of the Summer Palace Park, Beijing, China, reproduced with permission from reference ⁷⁶	20
Figure 1.13: Schematic diagram showing the <i>in situ</i> preparation of polymer monolithic capillary columns	22
Figure 1.14: Examples of some monomers used in the preparation of organic polymer monoliths ⁸²	25
Figure 1.15: Examples of some cross-linkers used in the preparation of organic polymer monoliths ⁸²	26
Figure 1.16: Examples of some free radical initiators used in the preparation of organic polymer monolith ⁸²	27
Figure 1.17: Chromatographic separation of three model proteins using poly (butyl methacrylate-co-ethylene dimethacrylate) capillary columns prepared by (A) thermal initiation and (B) photo initiation. Dashed lines represent overall backpressure in the system, reproduced with permission from reference ¹⁰⁴	28
Figure 1.18: Schematic diagram for the preparation of a silica monolith, reproduced with permission from reference ⁷⁶	32
Figure 1.19: Comparison between the internal structure of silica-based (a) and polymer-based (b) monolithic backbones, reproduced with permission from reference ⁹⁰	33
Figure 1.20: Scanning electron microscopy images of (a) hierarchically-structured silica-based monolithic materials with macropores and a relatively thin skeleton containing permanent	

mesopores, and (b) typical polymer-based monolithic materials with globular structures composed of cross-linked polymer, reproduced with permission from reference ⁷⁷	34
Figure 1.21: Schematic diagram showing MIP preparation. Functional monomers, cross-linker, template and radical initiator are mixed with the porogens. (1) The monomers form complexes with the template molecule (2) after polymerization the monomers are fixed in position by reaction with the cross-linker. (3) After extraction the recognition cavity, complementary to the template in size, shape, orientation and chemical functionality. The imprint is able to rebind the template with high selectivity, reproduced with permission from reference ¹³³	36
Figure 1.22: 2-hydroxyethylmethacrylate (N-L-valine-3,5-dianilide)carbamate functional monomer	37
Figure 1.23: N-methacryloyl-L-histidine methyl ester functional monomer.....	38
Figure 1.24: Schematic diagram for B-CD/GMA polymer monolithic columns, reproduced from reference ¹⁴⁴	39
Figure 1.25: Schematic diagram for β -CD polymer monolithic columns prepared via click chemistry, reproduced with permission from reference ¹⁴⁶	40
Figure 1.26: Schematic diagram for CD-GNP-modified monolithic columns, reproduced with permission from reference ¹⁵⁰	41
Figure 1.27: Enantioselective separation of hexobarbital on Chirasil-Dex monolith by rod-LC and rod-CEC, reproduced with permission from reference ¹⁵⁶	43
Figure 1.28: Schematic diagram showing the immobilization of CDPMC on a silica monolith, reproduced from reference ¹⁶⁰	45
Figure 1.29: Schematic diagram showing the preparation of β -CD-based silica monolith via one pot approach.....	46
Figure 1.30: Preparation of sulfonated β -CD silica monolith via post modification approach, reproduced from reference ⁴³	47

Figure 1.31: (<i>S</i>)- <i>N</i> -(4-allyloxy-3,5-dichlorobenzoyl)-2-amino-3,3-dimethylbutanephosphonic acid-based silica monolith, reproduced from reference ¹⁷⁰	48
Figure 1.32: Trans-(<i>1S,2S</i>)-2-(<i>N</i> -4-allyloxy-3,5-dichlorobenzoyl)aminocyclohexanesulfonic acid-based silica monolith, reproduced from reference ¹⁷¹	48
Figure 2.1: Vinylization of the inner capillary wall to enable polymer anchor, reproduced with permission from reference ²	76
Figure 2.2: Steps showing the preparation of polymer monolithic capillary columns:	78
Figure 2.3: Four-meter silica coils surface modified prior to sol-gel reaction	79
Figure 2.4: First heat treatment to induce mesopores formation carried out in the presence of urea solution. The program is finished once the temperature settles at 40°C.....	80
Figure 2.5: Second heat treatment: drying and sintering of the silica monolith. The program is finished once the temperature settles at 40°C.....	81
Figure 2.6: Steps showing the preparation of silica monolithic capillary columns:	79
Figure 2.7: Preparation of the capillary sections for SEM.....	83
Figure 3.1: Schematic diagram showing the composition of the monolith backbone	89
Figure 3.2: Scanning electron micrograph of M1 at 500x (left) and 25,000x (right) showing a homogenous porous monolithic structure with large macropores and microglobules	95
Figure 3.3: Scanning electron micrograph of M at 500x (left) and 25,000x (right) showing a dense monolithic structure with small macropores and microglobules	95
Figure 3.4: Scanning electron micrograph of M1P at 500x (left) and 5,000x (right) showing a highly dense monolithic structure with small macropores and microglobules.....	96
Figure 3.5: Column backpressure versus mobile phase flow rate of different prepared monoliths, mobile phase: acetonitrile/water 80:20 (v/v)	98

Figure 3.6: Retention factors of ketoprofen, naproxen and ibuprofen versus acetonitrile concentration, mobile phase acetonitrile: water (0.1% TFA), separated on M1 column (150 μm ID, 25 cm), flow rate 0.3 $\mu\text{L}/\text{min}$, injection volume 0.2 μL , UV 219 nm	100
Figure 3.7: Retention factors of propranolol, pindolol and acebutolol versus ammonium ion concentration, mobile phase ammonium acetate (5-25 mM, pH 7.5): acetonitrile (0.1% TFA) 70:30 v/v, separated on M1 column (150 μm ID, 25 cm), flow rate 0.3 $\mu\text{L}/\text{min}$, injection volume 0.2 μL , UV 254 nm.....	101
Figure 3.8: Separation of ketoprofen and propranolol on M1column (150 μm ID, 25 cm), acetonitrile/water (0.1% TFA) 90:10 v/v, flow rate 0.3 $\mu\text{L}/\text{min}$, injection volume 0.2 μL , UV 219 nm	103
Figure 3.9: Separation of ketoprofen, cizolirtine and hexaconazole on M1column (150 μm ID, 25 cm), acetonitrile/water (0.1% TFA) 85:15 v/v, separated on M1 column (25 cm, 150 μm ID), flow rate 0.3 $\mu\text{L}/\text{min}$, injection volume 0.2 μL , UV 219 nm.....	103
Figure 3.10: Chiral separation of ibuprofen on HSA-based silica monolith, reproduced with permission from reference ⁵²	106
Figure 3.11: Chiral separation of benzoïn on OVM-encapsulated silica monolith, reproduced with permission from reference ⁶²	107
Figure 3.12: Schematic diagram showing the polymer composition of G1L monolith.....	110
Figure 3.13: Schematic diagram showing the preparation of the lipase-immobilized GSL monolith	112
Figure 3.14: Schematic diagram showing the encapsulation technique	113
Figure 3.15: Scanning electron micrograph of G1 at 500x (left) and 5,000x (right) showing a homogenous porous monolithic structure with sufficient surface area for protein immobilization	116
Figure 3.16: Scanning electron micrograph of G1L at 500x (top) and 25,000x (bottom).....	118
Figure 3.17: Scanning electron micrograph of GSL at 500x (top) and 25,000x (bottom)	119

Figure 3.18: Scanning electron micrograph of M1 (top) vs M1L (bottom) at 500x (left) and 25,000x (right) showing a slight variation in the monolithic structure upon lipase encapsulation	120
Figure 3.19: Scanning electron micrograph of G3 at 500x (left) and 5,000x (right).....	121
Figure 3.20: Enantioselective nano-LC separation of atenolol on a blank lipase-free GMA column (top) and GL1 capillary column (bottom) (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	123
Figure 3.21: Enantioselective nano-LC separation of arterenolol on GL1 capillary column (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	124
Figure 3.22: Enantioselective nano-LC separation of chlorpheniramine on GSL capillary column (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 50:50 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	124
Figure 3.23: Enantioselective nano-LC separation of racemic-nomifensine overlaid on D-nomifensine on M1L (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	125
Figure 3.24: Enantioselective nano-LC separation of desmethylcizolirtine on M1L (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	126
Figure 3.25: Enantioselective nano-LC separation of chlorpheniramine on M1L (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 25:75 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	126
Figure 3.26: Enantioselective nano-LC separation of celiprolol on G2 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	127
Figure 3.27: Enantioselective nano-LC separation of normetanephrine on a blank lipase-free GMA column (top) and on G2 (bottom) (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	128

Figure 3.28: Enantioselective nano-LC separation of chlorpheniramine plain silica column (top) and on SL (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 80:20 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	129
Figure 3.29: Enantioselective nano-LC separation of miconazole on SL (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 40:60 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	130
Figure 3.30: Chromatograms a-c showing the UV traces of the enantioselective nano-LC separation of atenolol on G2 capillary column (150 μm ID, 25 cm length). (a) Racemic atenolol, (b) (<i>R</i>)-atenolol, (c) co-injected (<i>R</i>)-atenolol with racemic atenolol: (<i>R</i>)+(<i>R,S</i>), Mobile phase: methanol/water (0.1% TFA) 30:70 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	131
Figure 3.31: Enantioselective nano-LC separation of sulconazole on G3 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 50:50 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	132
Figure 3.32: Derivatization of G1L hydroxyl group into a hydrophobic derivative	136
Figure 3.33: Course of enantioselective hydrolysis of ibuprofen butanoate using CALB-immobilized capillary micro-bioreactor on Chiralpak IB (4.6 mm ID, 25 cm length). Mobile phase: <i>n</i> -hexane/TBME/TFA 90:10:0.1 v/v/v, UV: 219 nm, flow rate: 1 mL/min	138
Figure 4.1: Schematic diagram showing the structures of the most widely characterized CDs.	147
Figure 4.2: Enantiomer separation of barbituric acids on a Chiralpak-Dex monolith by CEC, reproduced with permission from reference ¹¹	149
Figure 4.3: Schematic diagram showing the preparation of 2,3,6-tris(phenylcarbamoyl)- β -CD-6-methacrylate.....	153
Figure 4.4: Schematic preparation of the anchor group MAS	156
Figure 4.5: Schematic diagram for the preparation of β -cyclodextrin-modified silica monolith	157
Figure 4.6: Schematic diagram showing the preparation of β -CD functionalized polymer monolith	159

Figure 4.7: Scanning electron micrograph of A1 at 500x (left) and 25,000x (right) showing a homogenous porous monolithic structure.....	162
Figure 4.8: Scanning electron micrograph of A2 at 500x (left) and 25,000x (right) showing a homogenous porous monolithic structure.....	162
Figure 4.9: Scanning electron micrograph of A3 at 500x (left) and 25,000x (right) showing a fine monolith with separation from the capillary walls	163
Figure 4.10: Overlay of A1 and A2 column backpressures versus flow rate	164
Figure 4.11: Scanning electron micrograph of bare silica monolithic column at 500x (top) and 25,000x (bottom) showing a homogenous porous monolithic structure.....	166
Figure 4.12: Evaluation of MAS coverage of the hybrid-type monolithic silica capillary (100 μm ID, 25 cm), mobile phase: THF/ <i>n</i> -hexane 15:85 v/v, UV: 254 nm, flow rate 0.005 mL/min, 2 μL injection volume of 1:1 toluene: benzanilide (in mobile phase). $k = 1.53$	167
Figure 4.13: Scanning electron micrograph of MAS-modified monolithic column at 500x (top) and 25,000x (bottom) showing a homogenous porous monolithic structure without any apparent agglomeration	168
Figure 4.14: Scanning electron micrograph of SCD1 (a), SCD2 (b) and SCD3 (c) at 500x (left) and 25,000x (right) showing the morphology of the prepared monoliths	169
Figure 4.15: Enantioselective nano-LC separation of propranolol on the polymer-based monolithic capillary column A2 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	171
Figure 4.16: Enantioselective nano-LC separation of tertatolol on the polymer-based monolithic capillary column A2 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 270 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	171
Figure 4.17: Enantioselective nano-LC separation of metoprolol on the polymer-based monolithic capillary column A2 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	172

Figure 4.18: Chromatograms a-c showing the UV traces of the enantioselective nano-LC separation of cizolirtine on A2 capillary column (150 μm ID, 25 cm length). (a) Racemic cizolirtine, (b) (*S*)-cizolirtine, (c) co-injected (*S*)-cizolirtine with racemic cizolirtine: (*S*)+(*R,S*), Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 173

Figure 4.19: Chromatograms a-c showing the UV traces of the enantioselective nano-LC separation of alprenolol on A2 capillary column (150 μm ID, 25 cm length). (a) Racemic alprenolol, (b) (*S*)-alprenolol, (c) co-injected (*S*)-alprenolol with racemic alprenolol: (*S*)+(*R,S*), Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 174

Figure 4.20: Enantioselective nano-LC separation of celiprolol on the polymer-based monolithic capillary column A2 (150 μm ID, 25 cm length). Mobile phase: methanol/water (0.1% TFA) 10:90 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 175

Figure 4.21: Enantioselective nano-LC separation of miconazole on the silica-based monolithic capillary column SCD2 (100 μm ID, 15 cm length). Mobile phase: methanol/water (0.1% TFA) 20:80 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 176

Figure 4.22: Enantioselective nano-LC separation of chlorpheniramine on the silica-based monolithic capillary column SCD1 (top) and SCD2 (bottom) (100 μm ID, 15 cm length). Mobile phase: methanol/water (0.1% TFA) 80:20 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 177

Figure 4.23: Enantioselective nano-LC separation of nomifensine on the silica-based monolithic capillary column SCD1 (top) and SCD2 (bottom) (100 μm ID, 15 cm length). Mobile phase: methanol/water (0.1% TFA) 80:20 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 178

Figure 4.24: Enantioselective nano-LC separation separation of celiprolol on the silica monolithic column prepared in KIT (100 μm , 15 cm), mobile phase: methanol/water (0.1% TFA) 55:45 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 180

Figure 4.25: Enantioselective nano-LC separation of alprenolol on the silica monolithic column prepared in KIT (100 μm , 15 cm), mobile phase: methanol/water (0.1% TFA) 55:45 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$ 180

Figure 4.26: Enantioselective nano-LC separation of eticloprode on the silica monolithic column prepared in KIT (100 μm , 15 cm), mobile phase: methanol/water (0.1% TFA) 55:45 v/v, UV: 270 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	181
Figure 4.27: Enantioselective nano-LC separation of cizolirtine on the silica monolithic column prepared in KIT (100 μm , 15 cm), mobile phase: methanol/water (0.1% TFA) 55:45 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	181
Figure 4.28: Chromatogram showing the loss of chiral discrimination of A2 for propranolol acetate, chromatographic conditions same as Figure 4.15	185
Figure 5.1: The helicity of SWCNTs defined by the roll-up vector (n,m) and yields two enantiomers P and M, reproduced from reference ¹¹	193
Figure 5.2: (a) SEM and (b) TEM images of SWCNTs. (c) Raman spectra of SWCNTs showing radial-breathing mode (RBM), D- and G-band regions. (d) XPS survey-scan of SWCNTs at (e) C 1s and (f) O 1s regions	198
Figure 5.3: Raman spectra of SWCNT-monolith (left) vs a plain monolith (right)	199
Figure 5.4: Scanning electron micrograph of a) PS (at 500x (top left) and 25,000x (top right)) vs b) SNTS (at 500x (bottom left) and 25,000x (bottom right)) showing small microglobules with rough surface.....	202
Figure 5.5: Scanning electron micrograph of a) PG (at 500x (top left) and 25,000x (top right)) vs b) GNTS (at 500x (bottom left) and 25,000x (bottom right)) showing small microglobules with rough surface.....	203
Figure 5.6 : Column backpressure vs mobile phase flow rate for SPMA-based columns.....	204
Figure 5.7 Column backpressure vs mobile phase flow rate for GMA-based columns	204
Figure 5.8: Enantioselective nano-LC separation of racemic sulconazole on GMA-columns with different SWCNTs concentrations (150 μm ID, 20 cm length) showing the effect of SWCNTs on the retention, α and R_s . Chromatographic conditions: mobile phase: methanol/water (0.1% TFA) 45:55 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	207

Figure 5.9: Enantioselective nano-LC separation of chlorpheniramine on GNT50 (150 μm ID, 20 cm length). Mobile phase: methanol/water (0.1% TFA) 40:60 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	208
Figure 5.10: Enantioselective nano-LC separation of cizolirtine on GNT50 (150 μm ID, 20 cm length). Mobile phase: methanol/water (0.1% TFA) 40:60 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	208
Figure 5.11: Enantioselective nano-LC separation of miconazole on SNT10 (150 μm ID, 20 cm length). Mobile phase: methanol/water (0.1% TFA) 25:75 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	209
Figure 5.12: Enantioselective nano-LC separation of carbuterol on SNT10 (150 μm ID, 20 cm length). Mobile phase: methanol/water (0.1% TFA) 20:80 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	209
Figure 5.13: Enantioselective nano-LC separation of racemic-nomifensine overlaid on D-nomifensine on GNT50 (150 μm ID, 20 cm length). Mobile phase: methanol/water (0.1% TFA) 40:60 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	210
Figure 5.14: Chromatograms a-c showing the UV traces of the enantioselective nano-LC separation of celiprolol on GNT50 capillary column (150 μm ID, 20 cm length). (a) racemic celiprolol, (b) (<i>S</i>)-celiprolol, (c) co-injected (<i>S</i>)-celiprolol with racemic celiprolol: (<i>S</i>)+(<i>R,S</i>), Mobile phase: methanol/water (0.1% TFA) 20:80 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	211
Figure 5.15: Enantioselective nano-LC separation of chlorpheniramine on SNT10 (150 μm ID, 20 cm length). Mobile phase: methanol/2-propanol (0.1% TFA) 50:50 v/v, UV: 219 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	213
Figure 5.16: Enantioselective nano-LC separation of nomifensine on SNT10 (150 μm ID, 20 cm length). Mobile phase: methanol/2-propanol (0.1% TFA) 80:20 v/v, UV: 240 nm, flow rate: 0.3 $\mu\text{L}/\text{min}$	213
Figure 5.17: Schematic diagram showing the speculative mechanism of interaction between chlorpheniramine and SWCNTs	216

Figure 6.1: Amylose tris-(3-chlorophenylcarbamate).....	224
Figure 6.2: Enantioselective separation of racemic flavanone on chiralpak ID (4.6 mm ID, 250 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 254 nm, flow rate: 1 mL/min	226
Figure 6.3: Enantioselective separation of racemic carprofen on chiralpak ID (4.6 mm ID, 250 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 220 nm, flow rate: 1 mL/min. * is for 2-propanol.....	226
Figure 6.4: Enantioselective separation of racemic 1-acenaphthenol on chiralpak ID (4.6 mm ID, 250 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 254 nm, flow rate: 1 mL/min	227
Figure 6.5: Enantioselective separation of racemic 1-(2-chlorophenyl)ethanol on chiralpak ID (4.6 mm ID, 250 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 254 nm, flow rate: 1 mL/min.....	227
Figure 6.6: Enantioselective separation of racemic 6-hydroxyflavanone on chiralpak ID (4.6 mm ID, 250 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 254 nm, flow rate: 1 mL/min.....	228
Figure 6.7: Enantioselective separation of racemic thalidomide on chiralpak ID-3 (0.3 mm ID, 150 mm length). Mobile phase: <i>n</i> -hexane/2-propanol 30:70 v/v, UV: 219 nm, flow rate: 10 μ L/min. Adapted with permission from Marina Gwairgi (research project in Applied Science 2013, UC). * is for 2-propanol.....	228
Figure 6.8: Enantioselective separation of racemic 1-indanol on the conventional chiralpak ID (top) vs the capillary chiralpak ID-3 (bottom). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 254 nm, flow rate: 1 mL/min and 10 μ L/min respectively	230
Figure 6.9: Enantioselective separation of racemic naftopidil on the capillary (top) vs the conventional chiralpak ID (bottom). Mobile phase: <i>n</i> -hexane/2-propanol 90:10 v/v, UV: 219 nm, flow rate: 50 μ L/min and 1 mL/min respectively. * is for 2-propanol	231

List of Tables

Table 1.1: Main groups of chiral selectors arranged according to their origin and separation techniques	11
Table 2.1: Chemicals used for methacrylate polymerization.....	66
Table 2.2: Chemicals used for silica monolith preparation and testing.....	68
Table 2.3: Organic solvents used for HPLC	68
Table 2.4: Chemical structures and suppliers of the investigated racemates.....	70
Table 2.5: Other chemicals used in this study	74
Table 2.6: Chiral selectors	75
Table 3.1: Porogen composition of the prepared monoliths	92
Table 3.2: Hydrodynamic flow properties of the monolithic columns.....	97
Table 3.3: Run-to-run, column-to-column and batch-to-batch repeatability of M1 column (25 cm, 150 μm ID) for the analysis of ketoprofen, cizolirtine and hexaconazole mixture, mobile phase: acetonitrile/water (0.1% TFA) 85:15 v/v, flow rate 0.3 $\mu\text{L}/\text{min}$, injection volume 0.2 μL , UV 219 nm	104
Table 3.4: Measured nitrogen content in different columns	121
Table 3.5: Chromatographic conditions, separation and resolution factors for the baseline/acceptably-resolved racemates	133
Table 4.1: Polymer composition used in the prepared monoliths.....	154
Table 4.2: Monomer concentration used in the prepared silica monoliths	157
Table 4.3: Porosity and performance of the prepared polymer monoliths using propranolol, mobile phase: methanol/water (0.1% TFA) 10/90, flow rate: 0.3 $\mu\text{L}/\text{min}$	160

Table 4.4: Run-to-run, column-to-column and batch-to-batch repeatability of the monolithic columns comparing the retention times of propanol, mobile phase: methanol/water (0.1% TFA) 10/90 v/v, flow rate: 0.3 μ L/min.....	165
Table 4.5: Chromatographic conditions, separation and resolution factors for the baseline/acceptably-resolved racemates	182
Table 5.1: Retention and hydrodynamic flow properties of the prepared monolithic columns .	200
Table 5.2: Run-to-run, column-to-column and batch-to-batch repeatability of the SWCNTs-monolithic columns comparing the mean retention times of sulconazole 28.....	205
Table 5.3: Chromatographic conditions, separation and resolution factors for the baseline-resolved racemates.....	214
Table 6.1: Chromatographic conditions, separation and resolution factors for the baseline resolved compounds on chirapak ID (flow rate 1 mL/min) and ID-3 (flow rate 10 μ L/min for aminoglutithimide and thalidomide and 50 μ L/min for naftopidil).....	232

Abbreviations

ADMPC	Amylose tris(3,5-dimethylphenylcarbamate)
AGP	α 1-acid glycoprotein
AIBN	Azobisisobutyronitrile
B0	Column permeability
BSA	Bovine serum albumin
BuMA	Butyl methacrylate
CAGR	Compound annual growth rate
CCC	Countercurrent Chromatography
CDMPC	Cellulose tris(3,5-dimethylphenyl-carbamate)
CDs	Cyclodextrins
CE	Capillary electrophoresis
CEC	Capillary electrochromatography
CLC	Capillary liquid chromatography
CMPA	Chiral mobile phase additive
CS	Chiral selector
CSP	Chiral stationary phase
DCM	Dichloromethane
DMF	Dimethylformamide
DMPAP	2,2-Dimethoxy-2-phenyl-acetophenone
DMSO	Dimethylsulfoxide
EDMA	Ethyleneglycol dimethacrylate
EEO	Enantiomer elution order
ee _p	Enantiomeric excess of product
ee _s	Enantiomeric excess of starting material
EIA	Exercise-induced asthma
ER	Eudismic ratio
ϵ T	Total porosity
EtAC	Ethylacetate
FDA	Food and drug administration
GC	Gas chromatography
GMA	Glycidyl methacrylate
h	hour
HSA	Human serum albumin
HOMs	Highly ordered mesoporous silica monoliths
HPLC	High performance liquid chromatography
ID	Inner diameter

IOC	International Olympic committee
IPA	Isopropyl alcohol (2-propanol)
k	The retention factor
KIT	Kyoto Institute of Technology
LC	Liquid chromatography
MIP	Molecularly imprinted polymer
MMA	Methyl methacrylate
MP	Mobile phase
MS	Mass spectroscopy
MtBE	Methyl <i>tert</i> -butyl ether
MTMS	Methyltrimethoxysilane
N	Theoretical plate number
Nano-LC	Nano-liquid chromatography
NP	Normal phase
OD	Outer diameter
OVM	Ovomucoid
PEEK	Poly(ether-ether-ketone)
PO	Polar organic
POSC	Polar organic solvent chromatography
RP	Reversed phase
SA	Selectand
SCX	Strong cation exchange
SEM	Scanning electron microscopy
SFC	Supercritical fluid chromatography
SPMA	3-Sulfopropyl methacrylate
SWCNTs	Single-walled carbon nanotubes (SWCNTs)
TEOS	Tetraethoxysilane
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
TMOS	Tetramethoxysilane
USD	US Dollars
VBTA	Vinylbenzyl trimethylammonium
w/w	weight/weight
γ -MAPS	3-(trimethoxysilyl)propyl methacrylate